Pfizer Inc., of New York, completed the submission of a new drug application to the FDA for palbociclib, requesting approval of the compound in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer who have not received previous systemic treatment for their advanced disease.